US FDA cites misleading ad for periodontal treatment
26 May 2009
Sue Sutter
A journal ad for Dexcel Pharma Technologies' periodontal treatment PerioChip (chlorhexidine gluconate) fails to communicate any risk information, the US
FDA's division of drug marketing, advertising and communications (DDMAC) said in a recent warning letter.
PerioChip is approved as an adjunct...
Please Login to read the full article.
26 May 2009
Sue Sutter
PerioChip is approved as an adjunct...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Zerit, Tygacil and Brinavess in latest CHMP restrictions
- US Capitol Capsule: US drug shortages worsen, putting patients increasingly at risk
- US Capitol Capsule: Stem cell researchers breathe sigh of relief on vacated injunction
- US Capitol Capsule: Supreme Court takes another stab at refining US patent law
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
